AI-powered digital wound platform used by medical researchers to make clinical trials more accessible, efficient and equitable
Toronto, Ontario (Sept 15, 2021) – Swift Medical, the global leader in digital wound care, recently launched new technology to support medical researchers conducting decentralized clinical trials. This launch also marks Swift Medical’s entry into the clinical trial market, enabling the company to take on this growing $44 billion market.
Swift Medical’s core product, Swift Skin and Wound, is an AI-powered, digital wound platform that allows any patient or clinician to easily capture high-precision images of skin or wound conditions with any smartphone camera. Swift Skin and Wound autonomously determines clinical characteristics, tracks disease progression, enables remote communication, and securely shares patient data in real-time. Swift Medical’s technology is used by more than 4,000 healthcare organizations internationally, including health systems and providers across the continuum, academic institutions, research organizations and pharmaceutical companies.
The COVID-19 pandemic has severely impeded clinical trials – making participant recruitment, monitoring and retention more difficult, which has resulted in more expensive, delayed and sometimes cancelled clinical trials. With the implementation of public safety measures, participant access to trial sites was reduced by up to 80% at the onset of the pandemic. Further, as 70% of potential trial participants live over two hours from a trial site, remote clinical trials are vital to improving accessibility and equitability, especially for low-income, rural and physically impaired participants – which, in turn, will increase diversity in trial populations and efficacy of new clinical interventions.
As the need to analyze skin conditions during medical research is critical to many studies, Swift Medical is able to support clinical trials across multiple sites, whether in the clinic or the participant’s home, without the need for expensive equipment or extended travel. Our technology is a purpose-built tool that enables efficient and cost-effective decentralized clinical trials by allowing researchers to analyze skin and wound conditions imaged with any smartphone, from any location.
“Organizations conducting and managing clinical trials are facing unprecedented challenges caused by the pandemic, yet their research is needed now more than ever. We’ve already proven that the Swift Medical platform is a trusted solution for producing clinical-quality images, but now we see an opportunity to help researchers develop life-saving treatments in a faster, more efficient manner,” said Carlo Perez, co-founder and CEO of Swift Medical. “Even after the pandemic, decentralized clinical trials represent the future for medical research, enabling applications to power the next generation of data analysis and scientific discovery.”
Our technology produces 3D-generated models, enables automated region-of-interest detection, and calculates precise, clinically-validated measurements that eliminate data variability. Study coordinators can continuously monitor the effects of new medications or interventions on participants from any location; and with real-time reports and analytics, investigators can easily identify and analyze trends for each subject and study.
Some of the largest pharmaceutical companies and clinical research organizations in the world are already using Swift Medical’s technology across more than 50 sites in North America and Europe.
About Swift Medical
Swift Medical is the world leader in digital wound care. Their technology is used by over 4,000 healthcare organizations across the continuum of care to improve the prevention, treatment and management of wounds. To learn more about Swift Medical, visit them at: swiftmedical.com.
Swift Medical is rapidly growing their team to take on the wound care epidemic. If you’re interested in joining the team, please look into open job opportunities at: swiftmedical.com/about/careers/.